~ Pfizer commits $200,000 this year to support Canadian researchers ~
MONTREAL, June 23, 2011 /CNW/ - Pfizer Canada is launching a new
Psychiatry Research Awards Program aimed to advance clinical research
and patient care in psychiatry by supporting Canadian investigators in
their research efforts.
The Awards program is a competitive research grant open to all
researchers interested in psychiatric diseases and mental illness,
including physicians, academics and pharmacists. Two research grants
of $100,000 each will help fund innovative research in the fields of
major depressive disorder, schizophrenia, or bipolar disorder.
An independent external review committee comprised of Canadian medical
research experts will evaluate all submitted proposals and select the
grant recipients. This committee is chaired by Dr. Glenda MacQueen, MD,
PhD, FRCPC, Professor and Head of the Department of Psychiatry,
University of Calgary, Calgary, Alberta.
"Canada has truly led the way in its commitment to mental illness
research, and it is a privilege to be part of such a ground-breaking
and valuable program," says Dr. MacQueen. "By giving Canadian
researchers support for new initiatives, Pfizer is enabling them to
advance clinical knowledge around the prevention and management of
psychiatric disorders to reduce the burden associated with mental
As chair of the independent review committee, Dr. MacQueen's
responsibilities will include: leading the committee's activities to
review and award the grants; providing constructive feedback to
applicants; and, facilitation of the overall process.
Proposals will be requested once per year, and research topics may vary
from year-to-year. This year, eligible areas of study include clinical
research involving humans, or outcomes/ epidemiological research in the
areas of major depressive disorders, schizophrenia or bipolar disorder.
The Psychiatry Research Awards Program is the most recent initiative in
Pfizer's ongoing commitment to mental illness in Canada.
"At Pfizer Canada, we are proud to support innovative ideas that improve
patients' well-being and encourage the Canadian researchers to further
public understanding of mental illness," says Dr. Bernard Prigent, Vice
President, Medical Affairs, Pfizer Canada. "We've seen the impact of
research award programs in other health areas, and look forward to the
effect this new program will have on mental health care in Canada."
Additional information and application information can be found at www.PfizerCNS.ca. The submission deadline for the 2011 Psychiatry grant competition is
September 29, 2011.
MENTAL ILLNESS IN CANADA
One in five Canadians will personally experience a mental illness during
their lifetime.1 Mental illnesses can affect people of all ages, educational and income
levels, and cultures1 and are the result of a complex interplay of genetic, biological,
personality and environmental factors.1
Nearly three million Canadians will experience depression in their
lifetime,2 with most people affected being in their working years, between the
ages of 24 and 44.2 A major depressive disorder can occur once in a lifetime, or episodes
can be recurrent.3
Schizophrenia affects an estimated one in 100 Canadians and their
families.4 While the exact causes are unknown, it is believed the illness is
caused by a biochemical imbalance.4 Schizophrenia can impact anyone, but usually develops in late
adolescence or early adulthood.4
Bipolar disorder affects approximately 1.2 per cent of the adult
population.5 It usually begins in early adulthood, with the average age of onset
around 18 to 24 years,5 although it can sometimes start in childhood or as late as the 40s or
ABOUT PFIZER CANADA INC.
Pfizer Canada Inc. is the Canadian operation of Pfizer Inc, the world's
leading biopharmaceutical company. Pfizer discovers, develops,
manufactures and markets prescription medicines for humans and animals.
Pfizer Inc. invests more than US$7 billion annually in R&D to discover
and develop innovative life-saving and life-enhancing medicines in a
wide range of therapeutic areas. Our diversified health care portfolio
includes human and animal biologic and small molecule medicines and
vaccines, and many of the world's best-known consumer products. For
more information, visit www.pfizer.ca.
SOURCE PFIZER CANADA INC.
For further information:
| Stephanie Yack |
| Daphne Weatherby |
Pfizer Canada Inc.
Tel: 1-866-9PFIZER (973-4937)